Psychedelics and the essential importance of context

  title={Psychedelics and the essential importance of context},
  author={Robin Lester Carhart-Harris and Leor Roseman and Eline Haijen and David Erritzoe and Rosalind Watts and Igor Branchi and Mendel Kaelen},
  journal={Journal of Psychopharmacology},
  pages={725 - 731}
Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic psychedelics (5-HT2A receptor agonism and associated plasticity) that we believe render their effects… 

Figures from this paper

Grounded in Biology: Why the Context-Dependency of Psychedelic Drug Effects Means Opportunities, Not Problems for Anthropology and Pharmacology

Langlitz and colleagues wrote about clinically used psychedelic drugs and the possibility of a “moral psychopharmacology” earlier in this journal (1). They emphasized the context-dependency of the

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice

Physicians or psychotherapists involved in psychedelic-assisted psychotherapy need training in ways to accompany patients through this experience to promote positive outcomes and address potential side effects.

Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?

It is proposed that a model of psychedelic-induced plasticity combined with an adequate therapeutic context has prophylactic and transdiagnostic potential, implying that it could have a broad, positive impact on public health.

How do psychedelics work?

It is proposed that psychedelics initiate a cascade of neurobiological changes that manifest at multiple scales and ultimately culminate in the relaxation of high-level beliefs and the purpose of psychedelic therapy is to harness the opportunity afforded by this belief-relaxation to achieve a healthy revision of pathological beliefs.

Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research

Substantial data have been gathered in the past 30 years suggesting that psychedelics are a potent treatment for a variety of common psychiatric conditions, though the ideal means of employing these substances to minimize adverse events and maximize therapeutic effects remains controversial.

Predictors of Psychedelic Experience: A Thematic Analysis.

Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics. Better understanding of

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Investigation of changes in anxiety and depression scores before versus after psychedelic experiences in naturalistic contexts lends support to therapeutic potential of psychedelics and highlight the influence of pharmacological and non-pharmacological factors in determining response.

The frontiers of new psychedelic therapies: A survey of sociological themes and issues

A sociological lens on clinical psychedelic therapies is offered and three areas of sociological interest are critically examined: the of role advocacy in the advancement of scientific research and the destigmatisation of psychedelics; issues related to the medicalisation and pharmaceuticalisation; and integration into healthcare systems.

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models

It is argued that studies investigating the neurobiological effects of psychedelics in animal models, including the activity-based anorexia (ABA) rodent model, are particularly important to inform clinical applications, includingThe subpopulations of patients that may benefit most from psychedelic medicine.



The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

The view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health is bolstered, as data from a clinical trial assessing psilocybin for treatment-resistant depression confirmed this.

Psilocybin: Psychotherapy or drug?

  • G. Goodwin
  • Psychology
    Journal of psychopharmacology
  • 2016
This edition of the Journal of Psychopharmacology highlights two very similarly designed studies of the effects of the serotonergic agonist psilocybin on the psychological distress of cancer patients and shows that treatment effects correlate with a subjective scale to measure such experience.

Psychedelics in the treatment of unipolar mood disorders: a systematic review

The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions.

Constructing drug effects: A history of set and setting

Set and setting is a term which refers to the psychological, social, and cultural parameters which shape the response to psychedelic drugs. The concept is considered fundamental to psychedelic

Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study

Results indicate that citalopram amplifies the influence of the living conditions on mood in a dose-dependent manner, which provides a potential explanation for the variable efficacy of SSRIs and might lead to the development of personalized strategies aimed at enhancing their efficacy.

Psychedelics not linked to mental health problems or suicidal behavior: A population study

Overall, it is difficult to see how prohibition of psychedelics can be justified as a public health measure, after adjusting for sociodemographics, other drug use and childhood depression.

Serotonin and brain function: a tale of two receptors

This bipartite model purports to explain how different drugs (SSRIs and psychedelics) that modulate the serotonergic system in different ways, can achieve complementary adaptive and potentially therapeutic outcomes.

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.

Evidence that psilocybin enhances autobiographical recollection implies that it may be useful in psychotherapy either as a tool to facilitate the recall of salient memories or to reverse negative cognitive biases.

‘It's the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression

  • C. HarmerP. Cowen
  • Psychology, Biology
    Philosophical Transactions of the Royal Society B: Biological Sciences
  • 2013
The delay in the clinical effect of SSRIs can be explained by the time needed for this positive bias in implicit emotional processing to become apparent at a subjective, conscious level, and this process is likely to involve the re-learning of emotional associations in a new, more positive emotional environment.